Combination therapies for the treatment of hepatocellular carcinoma
US11833119B2 · kind B2 · utility
0Cited by
5References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 9, 2019 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | Jan 9, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma. The combination comprises an FGFR4 inhibitor and lenvatinib.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.